TwinBeech Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$648K Buy
+32,145
New +$863K 0.15% 192
2024
Q4
– Sell
-253,795
Closed -$3.9M – 582
2024
Q3
$3.9M Buy
+253,795
New +$4.23M 0.07% 296
2024
Q2
– Sell
-142,496
Closed -$2.63M – 498
2024
Q1
$2.63M Buy
+142,496
New +$3.53M 0.05% 303
2023
Q4
– Sell
-316,555
Closed -$6.6M – 615
2023
Q3
$6.6M Buy
316,555
+121,058
+62% +$3.29M 0.13% 217
2023
Q2
$4.68M Buy
195,497
+79,798
+69% +$1.77M 0.09% 246
2023
Q1
$2.18M Buy
+115,699
New +$2.2M 0.04% 359
2022
Q3
– Sell
-79,579
Closed -$1.12M – 591
2022
Q2
$1.12M Buy
+79,579
New +$1.49M 0.05% 307
2022
Q1
– Sell
-21,366
Closed -$499K – 471
2021
Q4
$499K Buy
+21,366
New +$430K 0.03% 423
2021
Q2
– Sell
-29,975
Closed -$773K – 424
2021
Q1
$773K Buy
29,975
+25,941
+643% +$1.14M 0.11% 229
2020
Q4
$216K Sell
4,034
-14,253
-78% -$708K 0.04% 403
2020
Q3
$754K Buy
+18,287
New +$790K 0.16% 192

Other funds holding ACAD

TwinBeech Capital's ACAD Position: Q3 2026 in Review

TwinBeech Capital opened a new position in Acadia Pharmaceuticals (ACAD) in Q3 2026: 32,145 shares worth $648K. The stake represents 0.15% of the portfolio and ranks #192 among its holdings. This is a return to the name: TwinBeech Capital previously reported a position in ACAD as recently as Q3 2024.

TwinBeech Capital first reported a position in ACAD in Q3 2020 and has held it in 11 quarters since. The position peaked at $6.6M in Q3 2023. 350 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • TwinBeech Capital held 32,145 shares of Acadia Pharmaceuticals worth $648K as of Q3 2026.
  • Acadia Pharmaceuticals was a new TwinBeech Capital position in Q3 2026.
  • Acadia Pharmaceuticals made up 0.15% of TwinBeech Capital's portfolio in Q3 2026, its #192 holding.
  • TwinBeech Capital first reported a position in Acadia Pharmaceuticals in Q3 2020 and has held it in 11 quarters since.
  • TwinBeech Capital's Acadia Pharmaceuticals position peaked at $6.6M in Q3 2023.
  • 350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on TwinBeech Capital's 13F filing for Q3 2026, filed 16 Nov 2026.